卢非酰胺最新公布价格表

Rufinamide is an anti-epileptic drug for the treatment of Lennox-Gastaut syndrome, and its price information is of great reference value for patients when choosing medication. Based on the latest market data, this article systematically introduces the price system, medication specifications and contraindications of this drug. Currently, rufinamide produced by Japan Eisai Company is priced at US$112 for 100mg*100 tablets and US$166 for 200mg*100 tablets. The prices may fluctuate depending on the region and purchasing channels.

The latest announced price of rufinamide

The global market price system is dominated by original drugs and has obvious regional differences. Drug pricing is affected by multiple factors such as patent protection, circulation costs and medical insurance policies. Patients should choose appropriate specifications based on actual needs.

Original drug price details

The market reference price of the brand drug rufinamide produced by Japan Eisai Company is US$112 for 100mg*100 tablets and US$166 for 200mg*100 tablets. Due to the difference in value-added tax, the price of products with the same specifications in the European market will increase by about 10%-15%.

Generic drug market

Indian pharmaceutical companies have launched generic products. The price of 100 mg is about 40%-50% of the original drug. Some Middle Eastern countries can obtain about 70% of the preferential price of the original drug through government centralized procurement. Due to patent protection in the U.S. market, only original drugs are currently on the market.

Drug prices will change depending on the purchasing channel and batch size. It is recommended to obtain real-time quotes from regular medical institutions. Some national medical insurance systems can provide partial cost reimbursement.

Preparation for rufinamide administration

Standardized medication regimen is crucial to ensure the therapeutic effect. From dosage adjustment to medication monitoring, every step requires strict implementation of medical guidance.

Dose adjustment plan

The recommended initial dose for adults is 400mg/day, taken in two divided doses, and can be increased by 400mg per week, with the maximum dose not exceeding 3200mg/day. Medication for children needs to be calculated based on body weight, with a starting dose of 10mg/kg/day. Patients with abnormal liver function need to reduce the dose by 25%-50%.

Drug monitoring requirements

At the beginning of treatment, blood routine and liver function need to be monitored weekly. The stabilization period can be changed to monthly review. The dose should be adjusted in time when adverse reactions such as drowsiness and dizziness occur. It is recommended to perform regular electrocardiogram examinations during medication to monitor QT interval changes.

The medication regimen should be dynamically adjusted according to individual responses, and the dosage should not be increased or decreased on your own. When changing brands, the transition must be made under the guidance of a doctor.

Contraindications of rufinamide

Clearly identifying the contraindication groups is an important prerequisite for safe medication. Certain physical constitutions and disease states may increase the risk of medication and require strict screening and elimination.

Absolute contraindications

It is strictly prohibited to be used by patients with familial short QT syndrome. It is prohibited for those allergic to rufinamide or excipients. Use is prohibited in patients with severe hepatic impairment (Child-Pugh class C). Medication is not recommended during the first three months of pregnancy.

Relatively contraindicated groups

Patients with moderate hepatic insufficiency need to reduce the dosage. Patients with depression need to be closely monitored when taking medication. Elderly people should start with a small dose and adjust carefully. Breastfeeding women need to weigh the pros and cons before taking medication.

Before taking medication, you should inform the doctor in detail about your past medical history and medication status, and conduct regular follow-up visits to evaluate the treatment response. If you have serious adverse reactions, you should seek medical attention immediately.